MTX Lung vs. Rheumatoid Lung Disease

Slides:



Advertisements
Similar presentations
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Pharmacologic Treatment of Pediatric Headaches El-Chammas K, Keyes J, Thompson N,
Advertisements

St John’s wort for major depression (Review) Linde, Berner & Kriston (2008/9)
Long-term predictive value of assessment of coronary atherosclerosis by contrast- enhanced coronary computed tomography angiography: meta- analysis and.
Early detection of pulmonary involvement in scleroderma patients By Mohamed Mostafa Metwally, MD, FCCP Assistant professor of chest diseases Assiut University.
Immunoglobulin plus prednisolone in severe Kawaski disease (RAISE study) Steph Borg 22 November 2012 SCH Journal Club.
A Systematic Review On The Hazards Of Aspirin Discontinuation Among Patients With Or At Risk For Coronary Artery Disease Giuseppe Biondi Zoccai Hemodynamics.
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Meta-Analysis of Randomized Trials Singh PP et al. Proc ASH 2013;Abstract 407.
Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin plus Cytarabine versus Placebo plus.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Ki-67 index cutoff value of 1% is a valuable prognostic biomarker for pulmonary carcinoids based on this large cohort. Our data also provide strong evidence.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
R1 정수웅.  Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause that occurs.
Should it be viewed as a single entity? Hypersensitivity pneumonitis Should it be viewed as a single entity? Venerino Poletti versus Athol Wells.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Prevalence and clinical risk factors for interstitial lung disease in rheumatoid arthritis in a resource limited setting A Dasgupta, P Bhattacharyya, S.
Date of download: 7/11/2016 From: Safety of Herpes Zoster Vaccine in the Shingles Prevention Study: A Randomized Trial Ann Intern Med. 2010;152(9):
A NEW LOOK AT RA Interactive Hot Topics Series
Title slide.
1 Stone RM et al. Proc ASH 2015;Abstract 6.
Presented at the American Diabetes Association
Meta-Analysis of a Possible Signal of Increased Mortality Associated with Cefepime Use Peter W. Kim, Yu-te Wu, Charles Cooper, George Rochester, Thamban.
Table 1. Baseline Characteristics of the 36,636 Study Subjects
Aspirin Associated With Reduced Mortality in Patients With CRC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
Anastasiia Raievska (Veramed)
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
Attal M et al. Proc ASH 2010;Abstract 310.
HOPE: Heart Outcomes Prevention Evaluation study
Recent Advances in Idiopathic Pulmonary Fibrosis
Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.
Subjects characteristics
Table 1 Characteristics of study population, by pneumococcal vaccination status. From: Prior Pneumococcal Vaccination Is Associated with Reduced Death,
Clinical outcome after SVR: Veterans Affairs
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
Bleeding and cancer risk in patients with vascular disease COMPASS Steering Committee and Investigators.
کارگاه کشوری آموزش نقد و داوری مقالات علمی‌
Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples.
on behalf of the ASCOT Investigators *Imperial College London, UK
CRASH 2 Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2):
Barrios C et al. SABCS 2009;Abstract 46.
Respiratory MCNs - Interstitial lung diseases
Pearls Presentation Use of N-Acetylcysteine For prophylaxis of Radiocontrast Nephrotoxicity.
Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications  T.-L. Liao, Y.-M.
LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2010
Multidisciplinary Perspectives on Interstitial Lung Diseases
BeSt Study: Patient Characteristics Total Population Female 67% Male % Age (years) Duration of symptoms (weeks) 23 Time diagnosis.
Faderl S et al. Proc ASCO 2011;Abstract 6503.
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
A: Kaplan-Meier estimate of time to first LLA
Effect of Obesity on Prognosis after Early Breast Cancer
Intro: Biomarkers in RA
Safety, efficacy, and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis Alexander Egeberg, MD PhD; Mathias Bo Ottosen,
ASPIRE CLASS 6: Interpreting Results and Writing an Abstract
The Role of Open Lung Biopsy in the Management and Outcome of Patients With Diffuse Lung Disease  Mordechai R Kramer, Neville Berkman, Bella Mintz, Simon.
Diagnostic criteria for idiopathic pulmonary fibrosis
Community-acquired pneumonia: the evolving challenge
pulmonary embolism protocol -- EMB review
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.
Volume 375, Issue 9719, Pages (March 2010)
The efficacy and safety of omalizumab in pediatric allergic asthma
Does cinnamon reduce fasting blood glucose in Type II diabetics?
COUNTERPOINT: Does Interstitial Pneumonia With Autoimmune Features Represent a Distinct Class of Patients With Idiopathic Interstitial Pneumonia? No 
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Clinical response in patients with early and established RA at month 24. *p
Nicholas Z. Kerin, MD, Sony Jacob, MD  The American Journal of Medicine 
Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.
Effect Modifiers.
Working Together to Diagnose Idiopathic Pulmonary Fibrosis
Eugenio Andraca-Carrera
Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF).
Presentation transcript:

MTX Lung vs. Rheumatoid Lung Disease MTX Hypersensitivity Pneumonitis Rheumatoid Lung Distiguishing Features Early after MTX use Long-Standing RA RF+ or RF- Strongly Seropositive Usually without Deformity Deformities, Nodules, & Extraarticular Sxs BAL: Lymphocytes BAL: Neutrophils Steroid Responsive No Steroid Response Very Good Prognosis Poor 10 yr. Survival 2013 Sep 13;3(9):e003132. doi: 10.1136/bmjopen-2013-003132. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. Hozumi H, Nakamura Y, Johkoh T, Sumikawa H, Colby TV, Kono M, Hashimoto D, Enomoto N, Fujisawa T, Inui N, Suda T, Chida K. Author information Abstract OBJECTIVES: To investigate the risk factors and prognosis associated with acute exacerbation (AE) in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). DESIGN: A retrospective case-control study. SETTING: A single academic hospital. PARTICIPANTS: 51 consecutive patients diagnosed with RA-ILD between 1995 and 2012. All patients fulfilled the diagnostic criteria of the American College of Rheumatology for RA. ILD was diagnosed on the basis of clinical presentation, pulmonary function tests, high-resolution CT (HRCT) findings and lung biopsy findings. MAIN OUTCOME MEASURES: Overall survival and cumulative AE incidence were analysed using Kaplan-Meier method. Cox hazards analysis was used to determine significant variables associated with AE occurrence and survival status. RESULTS: A total of 11 patients (22%) developed AE, with an overall 1-year incidence of 2.8%. Univariate analysis revealed that older age at ILD diagnosis (HR 1.11; 95% CI 1.02 to 1.21; p=0.01), usual interstitial pneumonia (UIP) pattern on HRCT (HR 1.95; 95% CI 1.07 to 3.63; p=0.03) and methotrexate usage (HR 3.04; 95% CI 1.62 to 6.02; p=0.001) were associated with AE. Of 11 patients who developed AE during observation period, 7 (64%) died of initial AE. In survival, AE was a prognostic factor for poor outcome (HR 2.47; 95% CI 1.39 to 4.56; p=0.003). CONCLUSIONS: In patients with RA-ILD, older age at ILD diagnosis, UIP pattern on HRCT and methotrexate usage are associated with the development of AE. Furthermore, AE has a serious impact on their survival. KEYWORDS: Rheumatology Arthritis Rheum. 2013 Dec 24. doi: 10.1002/art.38322. [Epub ahead of print] Methotrexate and lung disease in rheumatoid arthritis - A meta-analysis of randomized controlled trials. Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Objective Methotrexate has shown efficacy in treating several diseases, especially rheumatoid arthritis (RA). Methotrexate has been implicated as a causative agent in interstitial lung disease. Patients with RA may develop pulmonary manifestations of their disease and are at increased risk of respiratory infections. The aim of this study was to evaluate the relative risk of pulmonary disease among RA patients treated with methotrexate. Methods We searched Pubmed and Cochrane databases between 1st January 1990 and 1st February 2013 for double-blind randomised controlled trials of methotrexate versus placebo or active comparator agents in adults with RA. Studies with less than 100 subjects or of less than 24 weeks duration were excluded. Two investigators independently searched both databases. All authors reviewed selected studies. We compared relative risk (RR) differences using the Mantel-Haenszel random effects method. Results A total of 22 studies with 8584 participants met our inclusion criteria. Heterogeneity across the studies was not significant (I2 =3%), allowing combination of trial results. Methotrexate was associated with an increased risk of all adverse respiratory events, RR 1.10(CI 1.02-1.19), and respiratory infections, RR 1.11(CI 1.02-1.21). Patients treated with methotrexate were not at increased risk of pulmonary death, RR 1.53(CI 0.46-5.01), or non-infectious respiratory events, RR 1.02(CI 0.65-1.60). A subgroup analysis of studies reporting pneumonitis revealed an increased risk with methotrexate, RR 7.81(CI 1.76-34.72). Conclusion Our study found a small but significant increase in the risk of lung disease in RA patients treated with methotrexate compared to other disease-modifying antirheumatic drugs and biologic agents. © 2013 American College of Rheumatology. Copyright © 2013 American College of Rheumatology. PMID: 24374778 *BAL: bronchoalveolar lavage Dawson Rheumatology2002;41:597; Salaffi F, Clin Rheumatol. 1997;16:296-304.